Turnstone biologics corp. reports third quarter 2023 financial results and provides recent business highlights

– promising preclinical data showcasing turnstone's novel selected til programs for solid tumors presented at sitc 2023 – – lead program, tidal-01, advancing and on track in two phase 1 trials with initial clinical data expected mid-2024 – – upsized ipo extends runway into q2 2025 and supports advancement of pipeline through key milestones – – further strengthened scientific advisory board with appointment of internationally recognized cancer immunotherapy expert, dr. jeffrey s. weber – san diego, nov. 09, 2023 (globe newswire) -- turnstone biologics corp. (“turnstone” or the “company”) (nasdaq: tsbx), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (selected til) therapy, today reported financial results for the quarter ended september 30, 2023, and provided recent business highlights.
TSBX Ratings Summary
TSBX Quant Ranking